Erasca Inc Quick Ratio (ERAS) starting from the second quarter 2026 to second quarter 2025, Financial Strength Trends, Rankings, Financial Ratios - CSIMarket
CSIMarket Company Name, Ticker, Competitors, else..
 


• Quick Ratio
• Working Capital
• LT Debt to Equity
• Debt to Equity
• Leverage Ratio
• Tangible Leverage
• Interest Coverage
• Debt Coverage
• Work. Cap. Per Revenue
Erasca Inc   (NASDAQ: ERAS)

Erasca Inc 's Quick Ratio

ERAS's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


Erasca Inc 's Cash & cash equivalent grew by 150.42 % in the Q2 2026 sequentially, faster than Current Liabilities, this led to improvement in Erasca Inc 's Quick Ratio to 16.41, above Erasca Inc average Quick Ratio.

Within Major Pharmaceutical Preparations industry 55 other companies have achieved higher Quick Ratio than Erasca Inc in second quarter 2026. While Quick Ratio total ranking has improved so far during the Q2 2026 to 240, from total ranking in the first quarter 2026 at 369.

Explain Quick Ratio?
How much Cash & cash equivalents ERAS´s has?
What are ERAS´s Current Liabilities?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

ERAS Quick Ratio (Jun 30 2026)
Q2		 (Mar 31 2026)
Q1		 (Dec 31 2025)
Q4		 (Sep 30 2025)
Q3		 (Jun 30 2025)
Q2
Y / Y Current Liabilities Change 32.14 % 4.68 % -9.19 % -4.37 % 13.09 %
Y / Y Cash & cash equivalent Change 103.05 % -19.96 % -7.45 % -9.57 % -26.38 %
Quick Ratio MRQ 16.41 9.14 9.68 10.04 10.68
ERAS's Total Ranking # 240 # 369 # 214 # 309 # 235
Seq. Current Liabilities Change 39.51 % -6.48 % -0.7 % 1.99 % 10.52 %
Seq. Cash & cash equivalent Change 150.42 % -11.7 % -4.27 % -4.08 % -1.29 %



Quick Ratio second quarter 2026 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 56
Healthcare Sector # 83
Overall Market # 240


Quick Ratio Statistics
High Average Low
25.99 12.36 7.54
(Sep 30 2021)   (Dec 31 2021)




Financial Statements
Erasca Inc 's Current Liabilities $ 37 Millions Visit ERAS's Balance sheet
Erasca Inc 's Cash & cash equivalent $ 610 Millions Visit ERAS's Balance sheet
Source of ERAS's Sales Visit ERAS's Sales by Geography


Cumulative Erasca Inc 's Quick Ratio

ERAS's Quick Ratio for the trailling 12 Months

ERAS Quick Ratio

 (Jun 30 2026)
12 Months		 (Mar 31 2026)
12 Months		 (Dec 31 2025)
12 Months		 (Sep 30 2025)
12 Months		 (Jun 30 2025)
12 Months
Y / Y Current Liabilities TTM Growth 5.25 % 0.23 % -4.9 % -6.83 % -3.14 %
Y / Y Cash & cash equivalent TTM Growth 16.06 % -16.64 % -17.59 % -16.85 % -13.37 %
Quick Ratio TTM 11.72 9.9 10.55 10.48 10.63
Total Ranking TTM # 3245 # 2693 # 1950 # 2437 # 2299
Seq. Current Liabilities TTM Growth 8.08 % 1.08 % -2.54 % -1.14 % 2.91 %
Seq. Cash & cash equivalent TTM Growth 27.94 % -5.2 % -1.87 % -2.5 % -8.1 %

Quick ratio ranking by company, industry and sector >> Back to ERAS Financial Strength Comparisons >> Go to Compare ERAS Quick Ratio to its Competitors

On the trailing twelve months basis ERAS Cash & cash equivalent more than doubled by 103.05 % in Q2 2026 year on year, faster than Current Liabilities, this led to increase in in Erasca Inc 's Quick Ratio to 11.72, Quick Ratio remained below ERAS average.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 411 other companies have achieved higher Quick Ratio than Erasca Inc . While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the first quarter 2026 from 2693 to 3245.

Explain Quick Ratio?
How much Cash & cash equivalents ERAS´s has?
What are ERAS´s Current Liabilities?

TTM Quick Ratio Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry # 412
Healthcare Sector # 833
Within the Market # 3245


trailing twelve months Quick Ratio Statistics
High Average Low
17.79 12.5 9.9
(Jun 30 2022)   (Mar 31 2026)




Companies with similar Quick Ratio in the quarter ending Jun 30 2026, within Major Pharmaceutical Preparations Industry Quick RatioJun 30 2026 MRQ Cash & cash equivalentJun 30 2026 MRQ Current Liabilities
Disc Medicine Inc   44.03 $ 1,336.770  Millions$ 30.360  Millions
Trevi Therapeutics Inc   36.50 $ 318.870  Millions$ 8.736  Millions
Design Therapeutics Inc   35.76 $ 401.889  Millions$ 11.240  Millions
Mineralys Therapeutics Inc   34.87 $ 673.704  Millions$ 19.319  Millions
Praxis Precision Medicines Inc   34.32 $ 1,683.790  Millions$ 49.058  Millions
Agios Pharmaceuticals Inc   33.94 $ 2,383.112  Millions$ 70.217  Millions
Mbx Biosciences Inc   33.10 $ 783.099  Millions$ 23.660  Millions
Xbiotech Inc   32.67 $ 109.528  Millions$ 3.353  Millions
Avalo Therapeutics Inc   31.89 $ 787.143  Millions$ 24.682  Millions
Fulcrum Therapeutics Inc   30.96 $ 318.840  Millions$ 10.298  Millions
Climb Bio Inc   30.86 $ 183.123  Millions$ 5.934  Millions
Indaptus Therapeutics Inc   29.61 $ 15.554  Millions$ 0.525  Millions
Crinetics Pharmaceuticals Inc   29.41 $ 2,350.275  Millions$ 79.915  Millions
Spyre Therapeutics Inc   28.48 $ 1,100.000  Millions$ 38.620  Millions
Curanex Pharmaceuticals Inc  28.17 $ 2.938  Millions$ 0.104  Millions
Onkure Therapeutics Inc   28.04 $ 186.284  Millions$ 6.643  Millions
Ligand Pharmaceuticals Incorporated  27.33 $ 1,277.438  Millions$ 46.736  Millions
Shattuck Labs Inc   26.94 $ 208.300  Millions$ 7.731  Millions
Cryoport inc   26.87 $ 785.860  Millions$ 29.244  Millions
Roivant Sciences Ltd   26.82 $ 7,607.076  Millions$ 283.603  Millions
Palvella Therapeutics Inc   26.23 $ 313.381  Millions$ 11.947  Millions
Upstream Bio Inc   26.16 $ 261.307  Millions$ 9.988  Millions
Rallybio Corporation  26.02 $ 92.800  Millions$ 3.567  Millions
Assembly Biosciences Inc   25.95 $ 608.475  Millions$ 23.445  Millions
Arbutus Biopharma Corp  25.84 $ 92.625  Millions$ 3.585  Millions
Immix Biopharma Inc   25.49 $ 238.715  Millions$ 9.364  Millions
Boundless Bio Inc   25.00 $ 194.230  Millions$ 7.768  Millions
Sionna Therapeutics Inc   24.88 $ 268.300  Millions$ 10.782  Millions
Prothena Corporation Public Limited Company  24.72 $ 288.193  Millions$ 11.658  Millions
Zenas Biopharma Inc   24.28 $ 1,597.761  Millions$ 65.818  Millions

Date modified: 2026-09-08T17:35:13+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.